The phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine therapy compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer at a high risk of recurrence demonstrated long-term impact.
In 1991, the National Breast Cancer Coalition demanded that the federal government spend $300 million more on breast cancer research. This push resulted in the creation of the Department of Defense Congressionally Directed Medical Research Program, which has broadened to 34 other diseases with an FY24 budget of $1.5 billion.
